

Charlottesville



Opioid-Related Claims Settlement

September 2025

Staff Contact: Ashley Reynolds Marshall

Charlottesville & Opioid Settlements

- In 2021, the City Council approved participation in the **Virginia Opioid Abatement Fund & Settlement Allocation**.
- This allowed Charlottesville to benefit from statewide opioid litigation without filing a lawsuit as an individual city.
- Prior settlements included major distributors, manufacturers, and retail pharmacies.
- Charlottesville's Estimated Totals FY 2022 through FY2042: **\$1,509,300.26**

Charlottesville's estimated 20-year total allocation is composed of: \$1,053,648.40 from *Manufacturer Direct Distribution*; \$364,521.49 from *eligible OAA Individual Distribution**; and \$91,130.37 from *eligible OAA Gold Standard Incentive** (*OAA Individual Distribution and Gold Standard Incentive funding totals equal what Charlottesville would qualify for should we submit successful applications and abide by all OAA rules and regulations*)

Additional Manufacturers

National settlements now available with: ***Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun, Zydus***

Total Settlement Nationwide: \$720 million from all parties

- Virginia specifically will receive up to *\$16.4 million*
 - Funds will be channeled through the Virginia Opioid Abatement Authority (OAA) for prevention, treatment, and recovery programs
 - City allocation is unknown at this time
- Funds are restricted for opioid remediation, prevention, and recovery efforts.
- Local participation requires Council authorization.

Next Steps for Charlottesville

- Approve City participation in the new settlements.
- Direct the City Attorney (and/or outside counsel) to execute documents and release claims.
- Action is consistent with the 2021 MOU and prior Council authorizations.
- Ensures Charlottesville secures its share of funding to address local opioid impacts.



Charlottesville